Trial Profile
A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Sep 2022
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms TRU-D
- 13 Apr 2022 Interim results (n=45) presented at the 113th Annual Meeting of the American Association for Cancer Research.
- 07 Aug 2019 Status changed from not yet recruiting to recruiting.
- 19 Jun 2019 Planned initiation date changed from 1 May 2019 to 1 Jun 2019.